||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Real-Time news about Prostrakan (London Stock Exchange): 0 recent articles
|diamondsales: What's going on may just be poker. If a higher bid is being prepared the last thing they will do is to make it obvious. Poker faces all round. At close on the Friday before the 130p bid the spread was very wide. That in itself was enough to deter buyers of the shares. A loss-making company, never paid a dividend, a wide spread? Stay clear, would be the normal market reaction, when in reality the share price was about to jump... A higher bid looks an odds on play but nothing is guaranteed. Worst way, if the 130p bid folds and nothing else comes in, I'm happy long term with my shares, accumulated from 63 pence up to 90 odd pence.|
|youwould: Key quote from their press release today, aside from the excellent growth in 2010....
"ProStrakan today announces that it has received approval from the FDA for Abstral (fentanyl) Sublingual Tablets.......Abstral will be the only rapidly- disintegrating sublingual tablet for breakthrough cancer pain on the US market, where the overall annual market value for immediate release fentanyl products is $550m (Source: Wolter Kluwers, August 2010. MAT).
Abstral is the first product to be approved in the US with the FDA mandated class-wide Risk Evaluation and Mitigation Strategy ("REMS") for transmucosal immediate release fentanyl products. The Abstral REMS allows appropriate prescriptions to be filled at retail pharmacies as well as providing access to Abstral within hospitals"
This is HUGE news - The US market have been desperate for a product like this for a long time. Abstral is far better than its closest rival Effentora which sells many millions $'s and is not even promoted currently..... with the salesforce that Prostrkan have trained and ready in the US Abstral is going to really fly....
and we still have news about Sancuso manufacturing, a new CEO and potential takeover to increase the share price further.
Sit tight on this one - the only way is up, up, up......|
|jdung: now share price is 49-50p.
maybe support at this price.
waiting for city boy big size trade..., then will go up..|
|brucie5: Chaps, you may well be right. But bear in mind that this is a company on the cusp of turning a profit, at a share price slightly less than half its peak, where there has been some decent, though not overwhelming director buying just above where we are now. Sales seem to be increasing, and there doesn't seem to be anything fundamentally wrong with the business model, even if sales of Sancuso were relatively disappointing. I struggle to find a negative analyst's report, and quite a lot of coverage has been far more positive than you at substantially higher levels.
I'd like to think that the chart is beginning to anticipate better news than you in August, though I agree that volume is thin. You undoubtedly know more than I. But then I have only just bought in.|
|jdung: now share price 95p, maybe "buy" at this price ?
trade line support at 95-105p. ??|
|the_doctor: Well done to the company - and the future looks bright
Looking at the testosterone market, Teva also has a gel in late stage development, so I'm unconvinced about the opportunity there.
Similarly, the fentanyl market is becoming increasingly competitive. There is also a reasonable risk of regulatory setbacks there.
Global Abstral sales are forecast to peak at about $200m
Given that PSK only gets royalties, it will only be getting a few £m for the first years, peaking at about £15m out to 2020.
Useful of course and the company will be profitable, but it'll need earnings of around £20m pa to justify this valuation ultimately
Near term years will largely be associated with paying off debt
So, IMO (just IMO) they'll need a few more growth driver products in.
With the share price strong, I'm expecting to see shares issued for an acquisition and/or to pay off debt. It would seem a good move.
|columb0: First quarter sales of Abstral for breakthrough pain should be interesting (launched in some EU countries in Jan 09). With US based Cephalon the only other competitor in the market at the moment, Prostrakan could establish a niche in Europe. IMO sales from this could double Prostrakan's revenue this year. Does anyone think that this kind of revenue boost is factored into the current share price?|
|columb0: Not share price movement despite FDA submission!
Is anyone tracking this stock?|
|paul p: I can't see a problem with the funding and from what I have read and seen from the company, everything was simply waiting for the FDA approval. Even in the current climate the share price is holding well around the £1 resistance level. In a very uncertain climate I am more than willing to have a punt on this one.|
|grimraider: Snouts in trough again and share price half what it was with no sign of any upward movement|
Prostrakan share price data is direct from the London Stock Exchange